GeoVax Comments on Recent Vaccine Development Study Funded by the Gates Foundation
Wednesday, September 19, 2018 10:44 AM

Atlanta, GA - (NewMediaWire) - September 19, 2018 - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on a research article describing a study funded by the Gates Foundation.  In the article, “Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model”, published at Gates Open Research1, the authors discussed their review of product development pipelines for 35 neglected diseases and over 500 product candidates, concluding there to be a worldwide funding gap over the next 5 years of between $1.5 and $2.8 billion, potentially impacting the development timelines of efficacious vaccines against HIV, Malaria and Tuberculosis.

David Dodd, GeoVax President & CEO, commented, “This study highlights the dire need for increased government and global health organization support for vaccine research and development against various pathogens afflicting humanity. Taking HIV as an example, and examining domestic spending in the United States alone, the federal funding budget request for 2018 includes $26.6 billion related to HIV/AIDS, of which less than $900 million (3%) is designated for domestic vaccine and other prevention research; the rest is mostly directed to care and treatment programs (Sources: Henry J. Kaiser Family Foundation, NIH Office of AIDS Research).  These numbers illustrate the stark reality of the ongoing economic burden of HIV/AIDS in the United States, and the dramatic impact that an effective preventive vaccine may have over time. A 2016 report from Research!America further quantifies the impact a vaccine could have on a global scale, stating that “Between 2020 and 2030, an AIDS vaccine could prevent between 5.2 and 10.7 million new HIV infections, saving between $46 billion to $95 billion from the averted costs of current HIV/AIDS treatments alone.” And the human impact in terms of quality of life and vitality is simply immeasurable.

NIH $3M Grant Will Enable Emory, Georgia Tech Researchers to Tackle Sickle Cell Disease with New Technologies
Tuesday, September 11, 2018 09:05 AM

The National Institutes of Health has awarded a four-year, $3 million grant to a research team at Emory and Georgia Tech that will use new technologies to improve the effectiveness of blood transfusions in patients with sickle cell disease.

The research will take place in the labs of Wilbur Lam, MD, PhD, and Melissa Kemp, PhD, both associate professors in the Coulter Department of Biomedical Engineering at Georgia Tech and Emory University, and at the University of Minnesota lab of David Wood, PhD. Lam is also part of the Aflac Cancer and Blood Disorders Center at Children’s Healthcare of Atlanta.

The NIH-funded project is entitled “Redefining clinical viscosity in sickle cell disease by leveraging microfluidic technologies.”

Sickle cell disease is a life-threatening genetic blood disorder in which red blood cells become physically altered and misshapen. Viscosity, or resistance to flow, is a complex biophysical property of blood that changes in various parts of the circulation in the body and is rendered even more complex by sickle cell disease.

Wright to absorb Cartiva and its arthritis cartilage implant in $435M deal
Wednesday, September 05, 2018 10:14 AM

Wright Medical Group announced plans to snatch up its competitor Cartiva, along with its synthetic cartilage implant for treating arthritis in the big toe, for $435 million in upfront cash.

Wright plans to fully fund the purchase through sales of equity securities, before the transaction is expected to close in the fourth quarter of this year. The deal, which does not include a financing contingency, has been approved by the boards of directors of both companies and by a vote of Cartiva’s stockholders.

Cartiva’s lead product is composed of a biocompatible, low-friction organic polymer that mimics natural cartilage and can be implanted at the base of the toe in about 35 minutes, allowing for a higher volume of procedures to be completed, compared to longer joint fusion operations using metal plates and screws that can inhibit motion. The implant received premarket approval in July 2016 as the first synthetic cartilage to be cleared by the FDA.

GeoVax and PharmaJet to Collaborate on Development of Needle-Free Vaccine for Zika Virus
Tuesday, August 21, 2018 12:17 PM

GeoVax Zika Virus Vaccine Provided 100% Protection in Animal Challenge Model

Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that it is collaborating with PharmaJet, Inc., on the evaluation of PharmaJet’s needle-free injection system for administration of GeoVax’s Zika vaccine.

The studies to be conducted pursuant to the collaboration will measure the efficacy of the GeoVax vaccine (designated GEO-ZM02) delivered by either syringe and needle or by the PharmaJet needle-free device. The studies will be conducted at the Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention (CDC) in Fort Collins, Colorado with technical assistance from the CDC. Further analysis will be conducted in the laboratories at GeoVax. PharmaJet is supplying its needle-free device and providing technical expertise.

In a previously published study, GeoVax demonstrated that GEO-ZM02 provided 100% protection in normal outbred mice challenged with a lethal dose of Zika virus (ZIKV) delivered directly into the brain. This is the only Zika vaccine in development based solely on the ZIKV NS1 protein, which provided full protection with a single-dose against a lethal ZIKV challenge using an immunocompetent mouse model.

GeoVax Announces Appointment of David Dodd as Chairman, President and Chief Executive Officer
Tuesday, August 14, 2018 09:23 AM

Current President & CEO Robert McNally to Retire Effective August 31 

ATLANTA, GA, August 14, 2018 GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that David A. Dodd, has been appointed President and Chief Executive Officer, effective September 1, succeeding Robert McNally, PhD, who has announced his retirement. Dr. McNally will remain as a member of the Company’s Board of Directors. 

“It has been a privilege to serve GeoVax, its shareholders and employees, but after 40 years in the life science industry with the last 10 years at GeoVax, I now look forward to a fulfilling retirement,” said Dr. McNally. “I remain committed to continuing to help advise and guide the company as a member of its Board of Directors and am very pleased that David Dodd has agreed to assume the role of President and CEO. David brings a wealth of experience from a successful career of leading and developing multiple companies in the life science industry. His familiarity with GeoVax vaccine targets and overall growth strategy are huge assets in moving the company forward. Also, as a long-term colleague and friend, I look forward to continuing to work with David.” 

<< first < Prev 1 2 3 4 5 6 7 8 9 10 Next > last >>

Page 7 of 37